Pharma Journalist 7836 posts 0 comments

In a few weeks’ time, industry’s foremost drug developers will be convening at the 5th Genome Editing Therapeutics Summit* (December 3-5 | Boston, MA), the only industry meeting…
Read More...

GSK plc and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T…
Read More...

Novartis announced that Scemblix (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed Philadelphia…
Read More...

Biogen Inc. and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and…
Read More...

Iterum Therapeutics plc announced that the U.S. Food and Drug Administration (FDA) has approved Iterum’s new drug application for ORLYNVAH (sulopenem etzadroxil and probenecid) for the…
Read More...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with…
Read More...

The 5th Genome Editing Therapeutics Summit (formerly the CRISPR 2.0 Summit) this December will be your foremost drug development focused gene editing meeting, providing you with the…
Read More...

AbbVie and Aliada Therapeutics announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier…
Read More...

Astellas Pharma Inc. announced the company's decision to withdraw its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal…
Read More...

Genome editing represents one of the most significant recent advancements in molecular biology. CRISPR/Cas9 has been seen by many as cutting-edge (if you can pardon the pun) for its…
Read More...